Oncocross Co., Ltd.

As of June 30, 2026, Oncocross Co., Ltd. carries a market capitalization of 46.59B, placing it among publicly traded companies globally. Its enterprise value stands at 30.36B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Oncocross Co., Ltd. has 12.20M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 116.78, and the price-to-book ratio stands at 3.44.

These figures are as of June 30, 2026. The EV/Sales ratio of 76.76 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 30.36B versus a market cap of 46.59B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Oncocross Co., Ltd. maintains a current ratio of 1.44, meaning it holds 1.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 65.91, indicating elevated leverage, while an interest coverage ratio of -6.58 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Oncocross Co., Ltd. posted a negative return on equity (ROE) of -42.57, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -25.80, reflecting losses generated across the asset base. The company generates approximately 10.48M in revenue per employee across its workforce of 37.75, a quick read on workforce productivity versus industry peers.

As of the close on October 23, 2026, Oncocross Co., Ltd.'s stock has declined approximately 62.98% over the past 52 weeks. The 50-day moving average sits at 3,489.10, while the 200-day moving average is 5,860.90.

Over the twelve months ended June 30, 2026, Oncocross Co., Ltd. generated 395.50M in revenue and converted that into -6.54B in net income, yielding earnings per share of -518.28. EBITDA reached -8.71B, while operating income came in at -9.78B.

As of June 30, 2026, Oncocross Co., Ltd. holds 25.17B in cash and equivalents against 8.94B in total debt, resulting in a net debt position of 8.33B. Total book value stands at 13.56B, with working capital of 8.12B providing operational flexibility.

Oncocross Co., Ltd. produced -7.16B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -2.41B in capital expenditures, free cash flow totaled -9.57B - equivalent to -791.41 per share.

These figures cover the twelve months ended June 30, 2026. The operating margin of -2,473.00 and net profit margin of -1,653.24 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -19.85: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -43.65, meaning Oncocross Co., Ltd. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, Oncocross Co., Ltd. has an Altman Z-Score of -1.79, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.